<DOC>
	<DOCNO>NCT02428764</DOCNO>
	<brief_summary>The purpose study study induction nimotuzumab plus gemcitabine carboplatin follow surgery see well work treat patient unresectable stage III squamous cell lung carcinoma .</brief_summary>
	<brief_title>Neoadjuvant Nimotuzumab Plus Gemcitabine Carboplatin Unresectable Stage III Squamous Cell Lung Carcinoma</brief_title>
	<detailed_description>Concurrent chemoradiotherapy recommend therapeutic approach patient unresectable stage III non-small cell lung cancer ( NSCLC ) , although surgery offer chance cure . With combined-modality therapy radiation therapy chemotherapy , prognosis stage III NSCLC remain poor . Nimotuzumab , human anti-EGFR monoclonal antibody , show efficacy treatment head/neck squamous cell carcinoma , nasopharyngeal carcinoma well lung cancer . This study study neoadjuvant nimotuzumab plus gemcitabine carboplatin follow surgery see well work treat patient unresectable stage III squamous cell lung carcinoma .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Target population unresectable stage III squamous cell lung carcinoma . Written inform consent provide . Male female patient age ≥18 year , ≤75 year . Able comply require protocol followup procedure , able receive oral medication . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Life expectancy ≥12 week . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥2.0 x 109/L , Platelet count ≥100 x 109/L , Hemoglobin ≥9 g/dL ( may transfuse maintain exceed level ) . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN subject without liver metastasis ; ≤ 5 x ULN subject liver metastasis . Adequate renal function : Serum creatinine ≤ 1.25 x ULN , ≥ 60 ml/min . Female subject pregnant breastfeeding . Known severe hypersensitivity nimotuzumab excipients product . Inability comply protocol study procedure . A serious concomitant systemic disorder , opinion investigator , would compromise patient 's ability complete study . A serious cardiac condition , myocardial infarction within 6 month , angina , heart disease . Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) . Patients prior chemotherapy therapy systemic antitumour therapy ( e.g . monoclonal antibody therapy ) . Patients prior radiotherapy History another malignancy last 5 year exception following : malignancy cure surgery alone continuous diseasefree interval 5 year permit . Cured basal cell carcinoma skin cure situ carcinoma uterine cervix permit . Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Evidence disease , neurological metabolic dysfunction , physical examination laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put subject high risk treatmentrelated complication . Patient active serious infection ( e.g . pyrexia 38.0℃ ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>